SWA
AQST icon

SFMG Wealth Advisors’s Aquestive Therapeutics AQST Stock Holding History

SFMG Wealth Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.1K Hold
13,766
– – ﹤0.01% 320
2025
Q4 		$88.9K Buy
+13,766
New +$85.8K 0.01% 303

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SFMG Wealth Advisors's AQST Position: Q1 2026 in Review

SFMG Wealth Advisors held its Aquestive Therapeutics (AQST) position steady in Q1 2026 at 13,766 shares worth $57.1K. The position accounts for ﹤0.01% of the portfolio, ranked #320.

SFMG Wealth Advisors first reported a position in AQST in Q4 2025 and has held it in 2 quarters since. The position peaked at $88.9K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • SFMG Wealth Advisors held 13,766 shares of Aquestive Therapeutics worth $57.1K as of Q1 2026.
  • SFMG Wealth Advisors left its Aquestive Therapeutics share count unchanged in Q1 2026.
  • Aquestive Therapeutics made up ﹤0.01% of SFMG Wealth Advisors's portfolio in Q1 2026, its #320 holding.
  • SFMG Wealth Advisors first reported a position in Aquestive Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • SFMG Wealth Advisors's Aquestive Therapeutics position peaked at $88.9K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on SFMG Wealth Advisors's 13F filing for Q1 2026, filed 12 May 2026.